RBC Capital analyst Leonid Timashev raised the firm's price target on Axsome Therapeutics to $302 from $242 and keeps an Outperform rating on the shares after its Q1 results. Auvelity in MDD - major depressive disorder - won a small topline beat, though spending grew faster than expected as the company advances toward its ADA launch in June and looks to several catalyst read-outs over FY26 to provide incremental upside, the analyst tells investors in a research note. RBC adds that it would buy the stock into strength.
